Market Overview

The Next Sector Rotation Will Be To Biotechs

The Next Sector Rotation Will Be To Biotechs

A sector rotation is common, particularly in times of market volatility. However, picking the timing and the right sector is always a concern for investors.

"There's always money coming out of something, going into something else," Joel Elconin, co-host of Benzinga's PreMarket Prep, said during Tuesday's daily show.

Dennis Dick, the show's co-host, jumped in and pointed that shares of Gilead Sciences, Inc. (NASDAQ: GILD) "got killed" following its earnings release, and Biogen Inc (NASDAQ: BIIB) has seen its shares "struggle for a while."

Related Link: Should Biotech Investors Take Hillary Clinton's Drug Pricing Plan Seriously?

Dick continued that there is a major overhang is the U.S. presidential election and delved into what affect a potential Clinton presidency would have on the entire drug sector, specifically regarding any new drug pricing policies.

"There is value here [in the biotech sector]," Dick said. "These companies make money."

As an example, Dick highlighted Pfizer Inc. (NYSE: PFE) as a standout as the company is expected to see $53 billion in revenue this year and offers a healthy dividend yield of 3.75 percent. Meanwhile, Gilead's stock boasts a P/E multiple of approximately 8 to 9.

Dick continued that investors who buy biotech stocks at current levels will be "happy" in five years from now. He did however caution there might be "short-term pain" given the U.S. election.

Posted-In: Benzinga PreMarket PrepAnalyst Color Biotech Politics Top Stories Exclusives Trading Ideas General Best of Benzinga


Related Articles (BIIB + GILD)

View Comments and Join the Discussion!

Latest Ratings

WEEDMKM PartnersMaintains30.0
NKTRH.C. WainwrightMaintains32.0
GOODNational SecuritiesInitiates Coverage On25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Good Fee News On Goldman ETFs

IPO Outlook: Do 4 Biotechs Mean Maybe The IPO Market Is Back?